You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

Meet the team

David Jolley BA (Hons), FREC

David Jolley BA (Hons), FREC

EVP & Country Head

After building a successful team supporting the European territories, David now leads our US organisation as EVP and Country Director based out of Raleigh, North Carolina. Holding a dual role with full accountability for setting and implementing the strategic direction of the country, he remains hands-on delivering his own portfolio of staffing and search business-critical projects.

David’s career in staffing and recruitment exceeds 17 years, the majority of which is embedded and dedicated to the Pharma, Biotech, and CRO sectors within life sciences. Prior to establishing Compass Life Sciences in the UK in 2018, he had worked for a decade within some of the largest and most innovative pharmaceutical organisations in the world within their HR and Talent Acquisition teams – at AstraZeneca, Roche, and Eli Lilly & Co.

During this time David worked across all levels of seniority giving him unique insights into the challenges in building teams and fostering innovative, and creative cultures. He has partnered with leadership teams to execute global staffing strategies to build diverse teams and delivered projects developing Employer Value Proposition (EVP), DE&I positioning, and board composition mandates.

With a track record delivering world-class talent for requirements across the globe, David has built up a rare blend of experiences that enables significant global reach to the most elusive of talent, whilst offering a pragmatic, and honest appraisal of all assignments he takes on.

Download full bio


Consultant Articles

Compass Life Sciences – CMO – Case Study

Compass Life Sciences exclusively partnered with an industry leading consultancy that provides best in class Medical Affairs consultancy to clients ranging from Big Pharma and Biotech through to emerging virtual...

Read more